Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Background Five-year follow-up in a trial involving patients with previously untreated stage
III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo)
as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma …

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

Improved understanding of the immune system and its role in cancer development and
progression has led to impressive advances in the field of cancer immunotherapy over the …

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with
ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to …

PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has
demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin …